Literature DB >> 33741897

Characteristics and outcomes of therapy-related myeloid neoplasms following autologous stem cell transplantation for multiple myeloma.

Kalyan Nadiminti1,2, M Hasib Sidiqi1, Kapil Meleveedu1,3, Hassan B Alkhateeb1, William J Hogan1, Mark Litzow1, Mrinal Patnaik1, Shaji Kumar1, Morie Gertz1, Dong Chen4, Mithun Vinod Shah5.   

Abstract

Entities:  

Mesh：

Year:  2021        PMID： 33741897      PMCID： PMC7979889          DOI： 10.1038/s41408-021-00454-y

Source DB:  PubMed          Journal:  Blood Cancer J        ISSN： 2044-5385            Impact factor:   9.812


× No keyword cloud information.
  14 in total

Review 1.  Pros and cons of frontline autologous transplant in multiple myeloma: the debate over timing.

Authors:  Shaji K Kumar; Francis K Buadi; S Vincent Rajkumar
Journal:  Blood       Date:  2018-12-26       Impact factor: 22.113

2.  Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.

Authors:  Lotfi Benboubker; Meletios A Dimopoulos; Angela Dispenzieri; John Catalano; Andrew R Belch; Michele Cavo; Antonello Pinto; Katja Weisel; Heinz Ludwig; Nizar Bahlis; Anne Banos; Mourad Tiab; Michel Delforge; Jamie Cavenagh; Catarina Geraldes; Je-Jung Lee; Christine Chen; Albert Oriol; Javier de la Rubia; Lugui Qiu; Darrell J White; Daniel Binder; Kenneth Anderson; Jean-Paul Fermand; Philippe Moreau; Michel Attal; Robert Knight; Guang Chen; Jason Van Oostendorp; Christian Jacques; Annette Ervin-Haynes; Hervé Avet-Loiseau; Cyrille Hulin; Thierry Facon
Journal:  N Engl J Med       Date:  2014-09-04       Impact factor: 91.245

3.  Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS).

Authors:  Sham Mailankody; Ruth M Pfeiffer; Sigurdur Y Kristinsson; Neha Korde; Magnus Bjorkholm; Lynn R Goldin; Ingemar Turesson; Ola Landgren
Journal:  Blood       Date:  2011-07-27       Impact factor: 22.113

4.  Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma.

Authors:  Catarina Maia; Noemi Puig; Maria-Teresa Cedena; Ibai Goicoechea; Rafael Valdes-Mas; Iria Vazquez; Maria-Carmen Chillon; Paula Aguirre; Sarai Sarvide; Francisco Javier Gracia-Aznárez; Gorka Alkorta; Maria-Jose Calasanz; Ramon Garcia-Sanz; Marcos Gonzalez; Norma C Gutierrez; Joaquin Martinez-Lopez; José J Perez; Juana Merino; Cristina Moreno; Leire Burgos; Diego Alignani; Cirino Botta; Felipe Prosper; Sergio Matarraz; Alberto Orfao; Albert Oriol; Ana-Isabel Teruel; Raquel de Paz; Felipe de Arriba; Miguel T Hernandez; Luis Palomera; Rafael Martinez; Laura Rosiñol; Maria-Victoria Mateos; Juan-Jose Lahuerta; Joan Blade; Jesus F San Miguel; Bruno Paiva
Journal:  Blood       Date:  2020-06-25       Impact factor: 22.113

5.  Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data.

Authors:  Antonio Palumbo; Sara Bringhen; Shaji K Kumar; Giulia Lupparelli; Saad Usmani; Anders Waage; Alessandra Larocca; Bronno van der Holt; Pellegrino Musto; Massimo Offidani; Maria T Petrucci; Andrea Evangelista; Sonja Zweegman; Ajay K Nooka; Andrew Spencer; Meletios A Dimopoulos; Roman Hajek; Michele Cavo; Paul Richardson; Sagar Lonial; Giovannino Ciccone; Mario Boccadoro; Kenneth Anderson; Bart Barlogie; Pieter Sonneveld; Philip L McCarthy
Journal:  Lancet Oncol       Date:  2014-02-11       Impact factor: 41.316

6.  Characteristics and outcomes of patients with multiple myeloma who develop therapy-related myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia.

Authors:  Naveen Pemmaraju; Dhaval Shah; Hagop Kantarjian; Robert Z Orlowski; Graciela M Nogueras González; Veera Baladandayuthapani; Nitin Jain; Verena Wagner; Guillermo Garcia-Manero; Jatin Shah; Farhad Ravandi; Sherry Pierce; Koichi Takahashi; Naval Daver; Aziz Nazha; Srdan Verstovsek; Elias Jabbour; Marcos De Lima; Richard Champlin; Jorge Cortes; Muzaffar H Qazilbash
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2014-07-15

7.  Therapy-related myelodysplastic syndrome/acute leukemia after multiple myeloma in the era of novel agents.

Authors:  Morie A Gertz; Evangelos Terpos; Angela Dispenzieri; Shaji Kumar; Rupin A Shah; Robert Orlowski; Efstathios Kastritis; Meletios A Dimopoulos; Jatin Shah
Journal:  Leuk Lymphoma       Date:  2014-11-03

8.  Lenalidomide maintenance after stem-cell transplantation for multiple myeloma.

Authors:  Michel Attal; Valerie Lauwers-Cances; Gerald Marit; Denis Caillot; Philippe Moreau; Thierry Facon; Anne Marie Stoppa; Cyrille Hulin; Lofti Benboubker; Laurent Garderet; Olivier Decaux; Serge Leyvraz; Marie-Christiane Vekemans; Laurent Voillat; Mauricette Michallet; Brigitte Pegourie; Charles Dumontet; Murielle Roussel; Xavier Leleu; Claire Mathiot; Catherine Payen; Hervé Avet-Loiseau; Jean-Luc Harousseau
Journal:  N Engl J Med       Date:  2012-05-10       Impact factor: 91.245

9.  Lenalidomide after stem-cell transplantation for multiple myeloma.

Authors:  Philip L McCarthy; Kouros Owzar; Craig C Hofmeister; David D Hurd; Hani Hassoun; Paul G Richardson; Sergio Giralt; Edward A Stadtmauer; Daniel J Weisdorf; Ravi Vij; Jan S Moreb; Natalie Scott Callander; Koen Van Besien; Teresa Gentile; Luis Isola; Richard T Maziarz; Don A Gabriel; Asad Bashey; Heather Landau; Thomas Martin; Muzaffar H Qazilbash; Denise Levitan; Brian McClune; Robert Schlossman; Vera Hars; John Postiglione; Chen Jiang; Elizabeth Bennett; Susan Barry; Linda Bressler; Michael Kelly; Michele Seiler; Cara Rosenbaum; Parameswaran Hari; Marcelo C Pasquini; Mary M Horowitz; Thomas C Shea; Steven M Devine; Kenneth C Anderson; Charles Linker
Journal:  N Engl J Med       Date:  2012-05-10       Impact factor: 91.245

10.  Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant.

Authors:  Tarek H Mouhieddine; Adam S Sperling; Robert Redd; Jihye Park; Matthew Leventhal; Christopher J Gibson; Salomon Manier; Amin H Nassar; Marzia Capelletti; Daisy Huynh; Mark Bustoros; Romanos Sklavenitis-Pistofidis; Sabrin Tahri; Kalvis Hornburg; Henry Dumke; Muhieddine M Itani; Cody J Boehner; Chia-Jen Liu; Saud H AlDubayan; Brendan Reardon; Eliezer M Van Allen; Jonathan J Keats; Chip Stewart; Shaadi Mehr; Daniel Auclair; Robert L Schlossman; Nikhil C Munshi; Kenneth C Anderson; David P Steensma; Jacob P Laubach; Paul G Richardson; Jerome Ritz; Benjamin L Ebert; Robert J Soiffer; Lorenzo Trippa; Gad Getz; Donna S Neuberg; Irene M Ghobrial
Journal:  Nat Commun       Date:  2020-06-12       Impact factor: 14.919
View more
  2 in total

1.  Therapy-related clonal cytopenia as a precursor to therapy-related myeloid neoplasms.

Authors:  Mithun Vinod Shah; Abhishek A Mangaonkar; Kebede H Begna; Hassan B Alkhateeb; Patricia Greipp; Ahmad Nanaa; Michelle A Elliott; William J Hogan; Mark R Litzow; Kristen McCullough; Ayalew Tefferi; Naseema Gangat; Mrinal M Patnaik; Aref Al-Kali; Rong He; Dong Chen
Journal:  Blood Cancer J       Date:  2022-07-08       Impact factor: 9.812

2.  Outcomes following venetoclax-based treatment in therapy-related myeloid neoplasms.

Authors:  Mithun Vinod Shah; Rakchha Chhetri; Ruchita Dholakia; Chung H Kok; Naseema Gangat; Hassan B Alkhateeb; Aref Al-Kali; Mrinal M Patnaik; Anmol Baranwal; Patricia T Greipp; Rong He; Kebede H Begna; Ing Soo Tiong; Andrew H Wei; Devendra Hiwase
Journal:  Am J Hematol       Date:  2022-05-27       Impact factor: 13.265
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.